TRAVERE THERAPEUTICS

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 янв 2023 18:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Corporate Update and 2023 Outlook

09 янв 2023 06:00:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 янв 2023 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 дек 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

16 ноя 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

15 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present at Upcoming Investor Conferences

09 ноя 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Third Quarter 2022 Financial Results

27 окт 2022 15:01:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

26 окт 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Third Quarter 2022 Financial Results

20 окт 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

13 окт 2022 15:05:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 окт 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 сен 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

25 авг 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics and CSL Vifor Announce EMA has Accepted for Review the Conditional Marketing Authorization Application for Sparsentan for the Treatment of IgA Nephropathy

22 авг 2022 06:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 авг 2022 16:00:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Second Quarter 2022 Financial Results

04 авг 2022 06:00:02 Источник Nasdaq GlobeNewswire

Travere Therapeutics Provides Regulatory Updates on its Development Programs

03 авг 2022 15:05:01 Источник Nasdaq GlobeNewswire

Travere Therapeutics to Report Second Quarter 2022 Financial Results

28 июл 2022 15:30:00 Источник Nasdaq GlobeNewswire

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 июл 2022 16:00:00 Источник Nasdaq GlobeNewswire